

Subject index

Volume 41 (1999)

2-5A-antisense; Respiratory syncytial virus; Oligonucleotides; Antiviral; RNase L **41**, 119

Acyclovir; Herpes simplex virus; Latency; Nucleosides analogues; Famciclovir; Valaciclovir **41**, 85

Adamantane derivatives; Amant; Anti-HIV-1; Polyanionic matrix **41**, 135

Aerosol; Interferon; Therapy; Flavivirus; St. Louis encephalitis **41**, 57

AIDS; KNI-272; HIV-1 protease; HIV; Protease inhibitor **41**, 21

Amant; Adamantane derivatives; Anti-HIV-1; Polyanionic matrix **41**, 135

Anti-HIV-1; Adamantane derivatives; Amant; Polyanionic matrix **41**, 135

Antiretroviral resistance; Combination therapy; Polymerase fidelity **41**, 45

Antiviral compound; FHPI; Human cytomegalovirus (HCMV); p38 MAPK **41**, 101

Antiviral; Respiratory syncytial virus; Oligonucleotides; 2-5A-antisense; RNase L **41**, 119

Antiviral treatment; Multiple sclerosis; Herpesviruses; Demyelination; Valaciclovir **41**, 1

Cell viability; Cytomegalovirus; Colorimetric assay; HPMP; DHPG **41**, 35

Colorimetric assay; Cytomegalovirus; Cell viability; HPMP; DHPG **41**, 35

Combination therapy; Antiretroviral resistance; Polymerase fidelity **41**, 45

Cytomegalovirus; Cell viability; Colorimetric assay; HPMP; DHPG **41**, 35

Demyelination; Multiple sclerosis; Herpesviruses; Antiviral treatment; Valaciclovir **41**, 1

DHPG; Cytomegalovirus; Cell viability; Colorimetric assay; HPMP **41**, 35

DNA polymerase; Hepatitis B virus; HBsAg; Lamivudine-related mutations; Ganciclovir **41**, 113

Dose variability; Virus inactivation; One-hit model; Kinetics models **41**, 145

Famciclovir; Herpes simplex virus; Latency; Nucleosides analogues; Acyclovir; Valaciclovir **41**, 85

FHPI; Antiviral compound; Human cytomegalovirus (HCMV); p38 MAPK **41**, 101

Flavivirus; Interferon; Therapy; Aerosol; St. Louis encephalitis **41**, 57

Ganciclovir; Hepatitis B virus; DNA polymerase; HBsAg; Lamivudine-related mutations **41**, 113

HBsAg; Hepatitis B virus; DNA polymerase; Lamivudine-related mutations; Ganciclovir **41**, 113

Hepatitis B virus; DNA polymerase; HBsAg; Lamivudine-related mutations; Ganciclovir **41**, 113

Herpes simplex virus; Latency; Nucleosides analogues; Acyclovir; Famciclovir; Valaciclovir **41**, 85

Herpesviruses; Multiple sclerosis; Demyelination; Antiviral treatment; Valaciclovir **41**, 1

HIV; KNI-272; HIV-1 protease; AIDS; Protease inhibitor **41**, 21

HIV-1 protease; KNI-272; AIDS; HIV; Protease inhibitor **41**, 21

HPMPC; Cytomegalovirus; Cell viability; Colorimetric assay; DHPG **41**, 35

Human cytomegalovirus (HCMV); FHPI; Antiviral compound; p38 MAPK **41**, 101

Interferon; Therapy; Flavivirus; Aerosol; St. Louis encephalitis **41**, 57

Kinetics models; Virus inactivation; One-hit model; Dose variability **41**, 145

KNI-272; HIV-1 protease; AIDS; HIV; Protease inhibitor **41**, 21

Lamivudine-related mutations; Hepatitis B virus; DNA polymerase; HBsAg; Ganciclovir **41**, 113

Latency; Herpes simplex virus; Nucleosides analogues; Acyclovir; Famciclovir; Valaciclovir **41**, 85

Multiple sclerosis; Herpesviruses; Demyelination; Antiviral treatment; Valaciclovir **41**, 1

Nucleosides analogues; Herpes simplex virus; Latency; Acyclovir; Famciclovir; Valaciclovir **41**, 85

Oligonucleotides; Respiratory syncytial virus; Antiviral; 2-5A-antisense; RNase L **41**, 119

One-hit model; Virus inactivation; Dose variability; Kinetics models **41**, 145

p38 MAPK; FHPI; Antiviral compound; Human cytomegalovirus (HCMV) **41**, 101

Polyanionic matrix; Adamantane derivatives; Amant; Anti-HIV-1 **41**, 135

Polymerase fidelity; Antiretroviral resistance; Combination therapy **41**, 45

Protease inhibitor; KNI-272; HIV-1 protease; AIDS; HIV **41**, 21

Respiratory syncytial virus; Oligonucleotides; Antiviral; 2-5A-antisense; RNase L **41**, 119

RNase L; Respiratory syncytial virus; Oligonucleotides; Antiviral; 2-5A-antisense **41**, 119

St. Louis encephalitis; Interferon; Therapy; Flavivirus; Aerosol **41**, 57

Therapy; Interferon; Flavivirus; Aerosol; St. Louis encephalitis **41**, 57

Valaciclovir; Herpes simplex virus; Latency; Nucleosides analogues; Acyclovir; Famciclovir **41**, 85

Valaciclovir; Multiple sclerosis; Herpesviruses; Demyelination; Antiviral treatment **41**, 1

Virus inactivation; One-hit model; Dose variability; Kinetics models **41**, 145